BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on Actilyse® powder and solvent for solution for injection and infusion (alteplase) for acute ischaemic stroke: important extension of indication to include adolescents under 16 years of age

2018.06.22

Active substance: alteplase

Actilyse® has been licensed for treatment of acute ischaemic stroke in adolescent patients under 16 years of age.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 330KB, File is accessible